Fulcrum Therapeutics, Inc. (FULC)
NASDAQ
Closed
Oct 23, 2026
Day's Range
3.6452 wk Range
2.83Overview - FULC - Fulcrum Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
-22.86M
P/E (Trailing)
-3.16
P/E (Forward)
-6.95
PEG Ratio
-0.14
Price / Book
0.93
EV / EBITDA
0.26
Profitability
Profit Margin
0.00%
Operating Margin
0.00%
Return on Assets
-19.59%
Return on Equity
-32.37%
Ownership
Shares Outstanding
76.28M
Float
63.49M
Short % of Shares Outstanding
9.29%
Held by Insiders
3.34%
Held by Institutions
103.50%
Price stats
Beta
2.58
50-Day Avg
3.77
200-Day Avg
6.93
Dividends
Payout Ratio
0.00%
Analyst Consensus
5 analysts
Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - FULC - Fulcrum Therapeutics, Inc.
Peers - FULC - Fulcrum Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- FULCNASDAQFulcrum Therapeutics, Inc.285.35MMarket Cap-131.82%52-week change-3.17P/E (Trailing)0.00%Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)32.26%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - FULC - Fulcrum Therapeutics, Inc.
About
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases. The company’s work centers on gene regulation and epigenetic control, using its discovery platform to identify drug targets that may address the root causes of…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
